|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, April 16, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, believes that pending catalysts and distinct advantages over its competition could help Synergy Pharmaceuticals (SGYP) achieve billion dollar status before long.
Summer Street initiated coverage with a price target of $9, Brean Murray's rating was accompanied by a price tag of $13, and just a couple of weeks ago Roth Capital threw its own prediction into the mix with a target of $12.
As of Tuesday afternoon, SGYP was trading for just a tad above the four dollar mark on below average volume, so what are the analysts seeing right now that investors have not yet caught on to?
The answer lies with the company's lead product candidate, Plecanatide, which has just recently reached the halfway enrollment point of an ongoing Phase II/III trial that, if successful, could quickly lead the stock to the price levels predicted by the analysts and position the company to enter into the gastrointestinal disorders & diseases market, which in the US alone is expected to exceed the $20 billion mark on an annual basis by the time Plecanatide would reach commercialization, according to some estimates.
Clinical trials are currently underway to test effectiveness of Plecanatide in treating chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C). The results of these trials are highly expected to turn out positive, as cited by the above-mentioned analysts, because the mechanism of action behind the treatment has already been tried and tested - and proven successful - with Linaclotide, a product developed by Ironwood Pharmaceuticals (IRWD) that shares origins with Plecanatide.
The mid and late stage successes of Linaclotide have launched Ironwood's share price to a over sixteen dollars at its peak during the past 52 weeks, which placed the company's market capitalization at right around a billion and a half.
Currently IRWD's market cap is roughly 1.3 billion.
Ironwood has already landed multiple partners for its product candidate and seen it's share price increase significantly. There's no reason to believe that Synergy cannot achieve the same level of success - if not more - for its own product, given the distinct advantages noted above and assuming the continued trend of positive efficacy.
Whether Synergy decides to go-it-alone or whether a partner is brought on board - or even whether the company is outright purchased - it's entirely possible that we are looking at a future billion dollar company in the making.
Judging by the price targets issued by the analysts over the past few weeks, it looks like there's at least a few out there who would tend to agree.
This one could become a big mover for 2012.
For full report visit: http://vfcsstockhouse.com/blog/article/-synergy-pharmaceuticals-sgyp-could-realize-billion-dollar-potential
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
The goal of VFC's Stock House is to bring new ideas, companies and discussions to investors and readers. With respect to the increased amount of time necessary to maintain quality, VFC's Stock House is at times compensated from third parties to research and cover certain companies that fit the profile of what interests the readers of VFC's Stock House. While taking compensation poses as an inherent perception of bias in coverage, the ultimate goal is to bring ideas and information to the eyes of readers, who can then decide what is and what is not relevant.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
